Cyclobenzaprine for relief of muscle spasm in acute musculoskeletal conditions

Cyclobenzaprine hydrochloride tablets are a prescription muscle relaxant used to relieve muscle spasms associated with acute, painful musculoskeletal conditions. They work centrally to reduce muscle hyperactivity without affecting muscle function. This medication is intended for short-term use and is typically combined with rest and physical therapy.

Cyclobenzaprine hydrochloride tablets are indicated as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions in adults. They should be used only for short periods, usually up to 2 or 3 weeks, as evidence for effectiveness beyond this duration is lacking and the condition is generally short-lived.

This medication is not effective for spasticity due to central nervous system disorders such as cerebral or spinal cord disease, and its safety and efficacy in pediatric patients under 15 years have not been established.

Cyclobenzaprine hydrochloride

Cyclobenzaprine acts primarily within the central nervous system, particularly at the brain stem level, to reduce tonic somatic motor activity affecting both gamma and alpha motor neurons. It does not act directly on skeletal muscles or neuromuscular junctions. Its pharmacologic effects resemble those of tricyclic antidepressants, with anticholinergic properties and sedation contributing to its muscle relaxant effect.

Adults: The usual dosing range is 5 to 10 mg taken orally three times a day. Therapy should be initiated at 5 mg, especially in the elderly or patients with hepatic impairment, with slow titration upward as needed. The treatment duration should not exceed 2 to 3 weeks.

In elderly patients and those with mild hepatic impairment, start with 5 mg and increase cautiously.

• Hypersensitivity to cyclobenzaprine or components of the product.
• Use of monoamine oxidase inhibitors concomitantly or within 14 days of discontinuation.
• Acute recovery phase of myocardial infarction.
• Patients with arrhythmias, heart block, conduction disturbances, or congestive heart failure.
• Hyperthyroidism.

Serotonin syndrome: The combination of cyclobenzaprine with other serotonergic drugs (SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors) may lead to life-threatening serotonin syndrome. Symptoms include mental status changes, autonomic instability, neuromuscular abnormalities, and gastrointestinal symptoms. Concomitant use with MAO inhibitors is contraindicated.

Cardiac risks: Cyclobenzaprine is related to tricyclic antidepressants and may cause arrhythmias, sinus tachycardia, and conduction delays. It is contraindicated in acute recovery from myocardial infarction and in patients with arrhythmias, heart block, congestive heart failure, or hyperthyroidism.

CNS depression: It may enhance the effects of alcohol, barbiturates, and other CNS depressants, impairing mental or physical abilities required for driving or operating machinery.

Common reactions: Drowsiness, dry mouth (more frequent than with diazepam), dizziness (less frequent than with diazepam).

Serious reactions: Potential central nervous system reactions similar to those with tricyclic antidepressants, arrhythmias, and serotonin syndrome when combined with serotonergic agents.

• Contraindicated with monoamine oxidase (MAO) inhibitors or within 14 days of their discontinuation due to risk of severe reactions including serotonin syndrome.
• Use caution when combined with other serotonergic drugs (SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil) due to risk of serotonin syndrome. Careful monitoring is advised, especially during initiation or dose increase.
• May enhance CNS depressant effects of alcohol, barbiturates, and other similar agents.
• Tricyclic antidepressant properties may reduce antihypertensive effects of guanethidine and similar agents; may increase seizure risk with tramadol.

Pregnancy: Category B. Animal studies at doses up to 20 times the human dose showed no harm to fertility or fetus. There are no adequate well-controlled studies in pregnant women, so use only if clearly needed.

Lactation: It is unknown if cyclobenzaprine is excreted in human milk. Due to structural similarity to tricyclic antidepressants, caution is advised when administered to nursing women.